<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571437</url>
  </required_header>
  <id_info>
    <org_study_id>MD-127-2019</org_study_id>
    <nct_id>NCT04571437</nct_id>
  </id_info>
  <brief_title>Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)</brief_title>
  <acronym>B-001</acronym>
  <official_title>Letrozole With or Without Metronomic Capecitabine in First Line Treatment of Patients With ER-positive HER2 Negative Advanced Breast Cancer: A Randomized Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II clinical trial designed to test the effect of combining endocrinal therapy&#xD;
      (Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of&#xD;
      female breast cancer with ER positive disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized clinical trial that assigns patients with female breast cancer in the&#xD;
      metastatic entity or advanced -beyond local disease treatment - entity into two arms. Arm A&#xD;
      contains Letrozole with metronomic Capecitabine versus arm B that contains Letrozole alone.&#xD;
      This is to be applied on ER positive HER2 negative tumours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are assigned into two arms of treatment, arm A contains Letrozole and metronomic Capecitabine while arm B contains Letrozole alone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months Progression free survival rate</measure>
    <time_frame>6 months from the start of treatment</time_frame>
    <description>Percentage of patients alive and progression-free at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months from the start of treatment</time_frame>
    <description>Rate of CR+PR as assessed by the investigator using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events rates in both groups</measure>
    <time_frame>6 months from the start of treatment</time_frame>
    <description>Rates of all grade (grade 1-4) and high grade (grade 3+4) adverse events as assessed by NCI-CTAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment using FACIT-B questionnare</measure>
    <time_frame>6 months</time_frame>
    <description>FACIT-B questionnare will be completed by each patient at baseline and 6 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression free survival</measure>
    <time_frame>18 months</time_frame>
    <description>comparison of estimated median PFS between both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>18 months</time_frame>
    <description>Time from start treatment to progression, death or treatment discontinuation from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>After 6 months of treatment</time_frame>
    <description>Complete response + partial response + stable disease for 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of patients alive at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to chemotherapy adminstration</measure>
    <time_frame>18 months</time_frame>
    <description>Time from randomization to the first chemotherapy administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemo endocrine treatment (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5mg PO daily + Capecitabine 500mg/m2 bid PO continously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endocrine treatment only (B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5mg PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine metronomic combined with Letrozole</description>
    <arm_group_label>Chemo endocrine treatment (A)</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole 2.5mg</intervention_name>
    <description>Letrozole daily alone</description>
    <arm_group_label>Chemo endocrine treatment (A)</arm_group_label>
    <arm_group_label>Endocrine treatment only (B)</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female sex&#xD;
&#xD;
          -  Age 18-70&#xD;
&#xD;
          -  ECOG-PS 0-II.&#xD;
&#xD;
          -  Histopathological proof of breast cancer&#xD;
&#xD;
          -  ER positive (Allred score of â‰¥3 out of 8), and HER2 negative by IHC (or ISH if HER2&#xD;
             +2).&#xD;
&#xD;
          -  Metastatic/recurrent disease as proven by CT scan, bone scan or clinical examination&#xD;
             (for skin lesions). Biopsy of the recurrent lesions is encouraged but not mandatory.&#xD;
&#xD;
          -  Either hormone sensitive setting (Denovo metastatic disease or disease progression&#xD;
             after more than 1 year of ending adjuvant endocrine therapy) or secondary resistance&#xD;
             to tamoxifen therapy (disease relapse after more than 2 years of starting and less&#xD;
             than 1 year of ending adjuvant endocrine therapy, or DP of metastatic disease after&#xD;
             more than 6 months of first line tamoxifen).&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Inadequate organ functions.&#xD;
&#xD;
          -  Disease progression while on prior aromatase inhibitor therapy.&#xD;
&#xD;
          -  Primary endocrine resistance.&#xD;
&#xD;
          -  Double primary cancer (history of other malignancy apart from a non melanoma skin&#xD;
             cancer).&#xD;
&#xD;
          -  Refusal to sign consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariam Saleh, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariam Saleh, M.D</last_name>
    <phone>+201003677227</phone>
    <email>mariamsaleh309@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Loay Kassem, M.D</last_name>
    <phone>+201003022907</phone>
    <email>loay.kassem@cairocure.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariam A Saleh, M.D</last_name>
      <phone>+201003677227</phone>
      <email>mariamsaleh309@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Loay Kassem, M.D</last_name>
      <phone>+201003022907</phone>
      <email>loay.kassem@cairocure.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mariam Saleh</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>Advanced breast cancer</keyword>
  <keyword>chemo-hormonal</keyword>
  <keyword>hormone positive</keyword>
  <keyword>metronomic capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

